|会社名||Biomerica Inc （バイオメリカ）|
|分野（sector）||Health Care ヘルスケア|
|業種||医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care）|
|概要||事業概要 Biomerica Inc. is a biomedical company which develops manufactures and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The Company''s medical diagnostic products are sold around the world in over two markets including clinical laboratories and point of care (physicians'' offices and over-the-counter drugstores). The Company operates in Europe the United States Asia South America the Middle East and other foreign countries. The Company''s diagnostic test kits are used to analyze blood urine or fecal specimens from patients in the diagnosis of various diseases and other medical complications or to measure the level of specific hormones antibodies antigens or other substances which exist in the human body in various concentrations. The Company primarily focuses on products for gastrointestinal (GI) food intolerances diabetes and esoteric tests. The Company''s diagnostic products use immunoassay technology. バイオメリカは米国の医療診断製品メ―カ―。病気の早期発見と慢性疾患のモニタリングのために血液、尿、便、ホルモン、抗原体などを測定するテスト・キットを開発・製造する。主に、糖尿病、胃腸疾患、食物不耐症などの診断やモニタリングに使用される。同社製品は酵素免疫測定技術に基づく。本社はカリフォルニア州ア―バイン。 Biomerica, Inc. is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on products for Gastrointestinal Disease, Diabetes and esoteric testing.|
|本社所在地||17571 Von Karman Avenue Irvine CA 92614 USA|
|代表者氏名||Zackary S. Irani ザッカーリS.イラン|
|代表者役職名||Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者|
|市場名||NASDAQ Small Cap|
|決算概要||決算概要 BRIEF: For the fiscal year ended 31 May 2018 Biomerica Inc. revenues decreased 4% to $5.6M. Net loss increased 61% to $1.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 24% to $1.4M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.11 to -$0.17.|
What Could Change After Biomerica Inc. (NASDAQ: BMRA) Gains 7.58% From The High-Point? 2022/07/30 18:00:00 Marketing Sentinel
Biomerica Inc. (NASDAQ:BMRA)’s traded shares stood at 0.1 million during the last session, with the company’s beta value hitting -0.34. At the close of trading, the stock’s price was $2.77, to imply an increase of 4.92% or $0.13 in intraday trading. The BMRA share’s 52-week high remains $7.38, putting it -166.43% down since that peak … What Could Change After Biomerica Inc. (NASDAQ: BMRA) Gains 7.58% From The High-Point? Read More »
Walmart to Start Selling Biomerica''s Aware Breast Self Exam Devices 2022/07/14 15:50:47 Benzinga
Biomerica Inc (NASDAQ: BMRA ) announced that its Aware Breast Self Exam device will now be sold in Walmart Inc''s (NYSE: WMT ) retail system. The Biomerica FDA-cleared Aware Breast Self Exam device is a way for women to enhance tactile sensitivity to changes or irregularities in breast tissue, … Full story available on Benzinga.com
Why U.S. Stocks Are Trading Lower Following Producer Inflation Data 2022/07/14 14:30:16 Benzinga
U.S. stocks traded lower this morning, following the release of economic reports on initial jobless claims and producer prices Following the market opening Thursday, the Dow traded down 1.92% to 30,182.23 while the NASDAQ fell 2.01% to 11,021.66. The S&P also fell, dropping, 2% to 3,725.83. Also check this: Markets In Extreme Fear With Rising Inflation Rates Leading and Lagging Sectors Consumer staples shares fell by just 1.1% on Thursday. Meanwhile, top gainers in the sector included Yatsen Holding Limited (NYSE: YSG ), up 14% and Bridgford Foods Corporation (NASDAQ: BRID ) up 8%. In trading on Thursday, energy shares dipped by 4.3%. Top Headline Producer prices for final demand rose 1.1% month-over-month in June, the mosy in three months and also above analysts’ expectations of 0.8%. Equities Trading UP SaverOne 2014 Ltd (NASDAQ: SVRE ) shares shot up 37% to $3.9501. SaverOne 2014 recently named Israel Eybi as Chief Marketing and Sales Officer. Shares of Biomerica, Inc. (NASDAQ: BMRA ) got a boost, shooting 25% to $3.71 following news the company''s breast self exam will …
Biomerica stock jumps after Walmart to begin selling co''s Aware Breast Self Exam device 2022/07/14 13:10:22 Seeking Alpha
Biomerica (BMRA) stock surged ~28% in Thursday premarket trading after the company said its Aware Breast Self Exam device will now be sold by Walmart (WMT).BMRA said that Walmart…
Walmart to Begin Selling Biomerica’s Aware Breast Self Exam 2022/07/14 12:19:00 Wallstreet:Online
Simple at-home device to increase sensitivity in breast self exams Early detection of breast cancer saves lives Breast Cancer accounts for 1 in 3 new cases of cancer in women annually IRVINE, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that under a General Merchandise Supplier Agreement with Walmart, the Company’s
Biomerica Receives Notice of Allowance from Canadian Patent Office for Patent Covering Irritable Bowel Syndrome (IBS) Food Sensitivity Testing & Treatment 2021/11/04 10:39:00 Intrado Digital Media
IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA ) today announced that the Canadian Patent Office has issued a notice of allowance for Biomericas patent application pertaining to the Companys InFoods® diagnostic guided therapy platform technology that offers a novel approach in the treatment of patients suffering from Irritable Bowel Syndrome (IBS). IBS is a chronic, often debilitating, functional gastrointestinal (GI) disorder with symptoms that include abdominal pain, bloating, and altered bowel behaviors, such as constipation and/or diarrhea, or alternating between the two.
Short Interest in Biomerica, Inc. (NASDAQ:BMRA) Expands By 66.2% 2021/10/31 08:16:45 Transcript Daily
Biomerica, Inc. (NASDAQ:BMRA) saw a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 1,320,000 shares, an increase of 66.2% from the September 30th total of 794,300 shares. Based on an average daily volume of 2,020,000 shares, the short-interest ratio is presently 0.7 days. Currently, 
Biomerica Launches New Website for Its Aware® Breast Exam Device 2021/10/29 12:19:00 Intrado Digital Media
IRVINE, Calif. , Oct. 29, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that in conjunction with Breast Cancer Awareness month, which takes place each October, it has launched its new website for the Aware ® at-home breast self-exam pad. Breast cancer is the most commonly-diagnosed cancer in women. In 2021, an estimated 281,550 new cases of invasive breast cancer will be diagnosed and approximately 43,600 women will die from breast cancer in US. One in eight women will develop invasive breast cancer in their lifetime.
Helicobacter Pylori Rapid Test Kit Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2027 | AccuBioTech, Alfa Scientific Designs, Association of Medicine and Analytics, Awareness Technology, BIOMERICA 2021/10/27 07:05:05 OpenPR
The “Helicobacter Pylori Rapid Test Kit Market” report describes in detail the demand and consumption of various products/services related to the market growth dynamics during the forecast period of 2021-2027. A detailed market assessment of the various opportunities in the
Biomerica inks exclusive distribution agreement in Canada for Helicobacter pylori test 2021/06/24 12:30:08 Seeking Alpha
Biomerica Signs Exclusive Distribution Agreement in Canada for its New and Proprietary Helicobacter Pylori (H. pylori) Test, hp+detect 2021/06/24 12:19:00 Wallstreet:Online
Prevalence of H. pylori infection in the United States is approximately 35% to 40% of the population IRVINE, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced that it has signed an exclusive five-year distribution agreement with a Canadian partner for the distribution and marketing of Biomericas new and proprietary Helicobacter pylori test, called hp+detect.
Biomerica Signs Exclusive Distribution Agreement in Canada for its New and Proprietary Helicobacter Pylori (H. pylori) Test, hp+detect 2021/06/24 12:19:00 Intrado Digital Media
IRVINE, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced that it has signed an exclusive five-year distribution agreement with a Canadian partner for the distribution and marketing of Biomericas new and proprietary Helicobacter pylori test, called hp+detect. The hp+detect product has been developed for the identification and monitoring of H. pylori infection, the leading cause of duodenal and gastric ulcers, and a contributing risk factor associated with gastric cancer. Physicians and medical centers can use hp+detect to diagnose the presence of H. pylori and to monitor the efficacy of treatment.
Biomerica Receives Notice of Allowance from Mexican Patent Office for Irritable Bowel Syndrome Food Sensitivity Testing & Treatment 2021/06/15 12:19:00 Intrado Digital Media
IRVINE, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA ) today announced that the Mexican Patent Office has issued a notice of allowance for Biomericas patent application pertaining to the Companys InFoods ® technology platform that offers a revolutionary approach in the treatment of patients suffering from Irritable Bowel Syndrome (IBS). Specifically, this allowed application contains claims that broadly cover the method that enables physicians to identify patient specific foods, such as milk, shrimp, broccoli, etc., that, when removed from the patients diet, may alleviate or improve an individuals IBS symptoms, including constipation, diarrhea, bloating, severe cramping, pain and indigestion.